Emerging Epigenetic and Posttranslational Mechanisms Controlling Resistance to Glucocorticoids in Acute Lymphoblastic Leukemia
Open Access
- 22 June 2023
- journal article
- review article
- Published by Wiley in HemaSphere
- Vol. 7 (7) , e916
Abstract
Glucocorticoids are extensively used for the treatment of acute lymphoblastic leukemia as they pressure cancer cells to undergo apoptosis. Nevertheless, glucocorticoid partners, modifications, and mechanisms of action are hitherto poorly characterized. This hampers our understanding of therapy resistance, frequently occurring in leukemia despite the current therapeutic combinations using glucocorticoids in acute lymphoblastic leukemia. In this review, we initially cover the traditional view of glucocorticoid resistance and ways of targeting this resistance. We discuss recent progress in our understanding of chromatin and posttranslational properties of the glucocorticoid receptor that might be proven beneficial in our efforts to understand and target therapy resistance. We discuss emerging roles of pathways and proteins such as the lymphocyte-specific kinase that antagonizes glucocorticoid receptor activation and nuclear translocation. In addition, we provide an overview of ongoing therapeutic approaches that sensitize cells to glucocorticoids including small molecule inhibitors and proteolysis-targeting chimeras.Keywords
This publication has 172 references indexed in Scilit:
- Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemiaNature Medicine, 2012
- Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosisLeukemia Research, 2011
- Transcription Factor AP1 Potentiates Chromatin Accessibility and Glucocorticoid Receptor BindingMolecular Cell, 2011
- CREBBP mutations in relapsed acute lymphoblastic leukaemiaNature, 2011
- Lysine 419 targets human glucocorticoid receptor for proteasomal degradationSteroids, 2010
- Glucocorticoid use in acute lymphoblastic leukaemiaThe Lancet Oncology, 2010
- NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemiaLeukemia, 2009
- Glucocorticoid Receptor Activation of the Ciz1-Lcn2 Locus by Long Range InteractionsJournal of Biological Chemistry, 2009
- γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemiaNature Medicine, 2008
- FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitorsJournal of Experimental Medicine, 2007